Compare Aurora Cannabis Inc (ACB) vs Fox Corp Class A (FOXA) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

FOXA trades at $55.87, down 1.08% with bearish technical signals despite strong fundamentals. The company reported robust earnings with Q1 2026 EPS of $1.32 beating expectations by 29%, continuing a trend of quarterly beats. Revenue grew to $16.3B in 2025 with net income margin expanding to 13.88%. However, the stock faces headwinds from the recent $22B Roku acquisition announcement, which has raised leverage concerns and contributed to recent price weakness.

The outlook remains balanced with 50% analyst buy ratings and a $67.80 consensus target suggesting 21% upside potential. Key risks include integration challenges from the Roku acquisition and streaming competition, while opportunities lie in advertising growth from World Cup events and Tubi streaming momentum. Valuation appears reasonable with P/E of 14.7x and EV/EBITDA of 8.4x.